Brown, Lisle/Cummings, Inc. Amarin Corp Plcuk Call Options Transaction History
Brown, Lisle/Cummings, Inc.
- $329 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AMRN
# of Institutions
177Shares Held
65.1MCall Options Held
258KPut Options Held
98K-
Sarissa Capital Management LP Greenwich, CT24.9MShares$11.4 Million3.89% of portfolio
-
Kynam Capital Management, LP Princeton, NJ12.4MShares$5.71 Million0.64% of portfolio
-
Eversept Partners, LP New York, NY3.31MShares$1.52 Million0.16% of portfolio
-
Morgan Stanley New York, NY2.55MShares$1.17 Million0.0% of portfolio
-
Scp Investment, LP2.5MShares$1.15 Million1.16% of portfolio
About AMARIN CORP PLCUK
- Ticker AMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 403,206,016
- Market Cap $185M
- Description
- Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...